Vyvgart Hytrulo — Medica

Initial criteria

• Patient is age ≥ 18 years
• Diagnosis of CIDP was supported by electrodiagnostic studies
• Patient meets ONE of the following: (a) Patient has previously received treatment with an intravenous or subcutaneous immune globulin AND had inadequate efficacy or significant intolerance; OR (b) Patient has a contraindication to intravenous or subcutaneous immune globulin
• Medication is prescribed by or in consultation with a neurologist

Reauthorization criteria

• Patient is age ≥ 18 years
• According to the prescriber, the patient has a clinically significant improvement in neurologic symptoms (e.g., improvement in disability, nerve conduction study results improved or stabilized, physical examination shows improved neurological symptoms, strength, and sensation)
• Medication is prescribed by or in consultation with a neurologist

Approval duration

initial: 3 months; reauthorization: 1 year